



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	O. FILING DATE FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/975,384	10/11/2001 Chad A. Mirkin		00-713-i13	9813		
75	90 11/17/2003	EXAM	EXAMINER			
Emily Miao	hara IIlham & Danahaff	RILEY,	RILEY, JEZIA			
McDonnell Boe	hnen Hulbert & Berghoff	ART UNIT	PAPER NUMBER			
300 S. Wacker Drive			1637	1637		
Chicago, IL 6	J606	DATE MAILED: 11/17/2003				

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	. No	Anntigent(s)				
			,	Applicant(s)				
	Office Action Summary	09/975,384		MIRKIN ET AL.	MIRKIN ET AL.			
	Omec Action Guilliary	Examiner		Art Unit				
_	The MAILING DATE of this communication and	Jezia Riley		1637				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
1) Responsive to communication(s) filed on								
2a)□	· · · · · · · · · · · · · · · · · · ·							
3)□								
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims								
4) Claim(s) 155 and 170 is/are pending in the application.								
4a) Of the above claim(s) is/are withdrawn from consideration.								
5) Claim(s) is/are allowed.								
6)⊠ Claim(s) <u>155 and 170</u> is/are rejected.								
7)	Claim(s) is/are objected to.							
	Claim(s) are subject to restriction and/or	r election red	quirement.					
Application Papers								
•	The specification is objected to by the Examiner							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.								
If approved, corrected drawings are required in reply to this Office action. 12) The oath or declaration is objected to by the Examiner.								
Priority under 35 U.S.C. §§ 119 and 120								
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a) All b) Some * c) None of:								
1. Certified copies of the priority documents have been received.								
2. Certified copies of the priority documents have been received in Application No								
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).								
* See the attached detailed Office action for a list of the certified copies not received.								
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.								
Attachment(s)								
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) <u>15</u>	5		nary (PTO-413) Paper No nal Patent Application (PT				

tale.

Application/Control Number: 09/975,384

Art Unit: 1637

DETAILED ACTION

Claim Rejections - 35 USC § 112

- 1. The following is a quotation of the second paragraph of 35 U.S.C. 112:
 - The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 2. Claims 155 and 170 recite the limitation "the oligonucleotides attached to the nanoparticles" in lines 6-7. There is insufficient antecedent basis for this limitation in the claims.

Claim Rejections - 35 USC § 103

- 3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Application/Control Number: 09/975,384

Art Unit: 1637

4. Claims 155 and 170 are rejected under 35 U.S.C. 103(a) as being unpatentable over Yguerabide et al. (6,214,560) in view of Hainfeld (5,521,289).

Yguerabide et al. discloses a method for the detection and measurement of one or more analytes in a sample. The method is based on the use of certain particles of specific composition, size, and shape and the detection and/or measurement of one or more of the particle's light scattering properties. The detection and/or measurement of the light-scattering properties of the particle is correlated to the presence, and/or amount, or absence of one or more analytes in a sample. The present invention is versatile and has utility in one form or another to detect and measure one or more analytes in a sample. One or more analytes in a sample can be detected and measured by detection and/or measurement of one or more of the specific light scattering properties of metal-like particles. (Summary of the Invention). For example, a certain nucleic acid analyte is composed of about 100 nucleic acid bases and is present in a sample. The sample is prepared so that this nucleic acid is in a single stranded form. Then two or more unique single-stranded "probe" nucleic acid sequences are added to the sample where these different probes bind to different regions of the target strand. Each of these probes has attached to one or more particles (col. 74). Further, the particles can form different types of aggregates that can be detected visually or instrumentally in a microscope or through macroscopic observation or measurements without having to separate free from analyte bound particles. The method provides for useful apparatus and particle types for specific test kits can be constructed. These different test kits, and associated apparatus are useful for

Application/Control Number: 09/975,384

Art Unit: 1637

applications to consumer use, portable field use, point of care applications such as doctor's offices, clinics, emergency rooms and the

Hainfeld et al. discloses small organometallic probes comprising a core of metal atoms bonded to organic moieties. The metal atoms are gold, silver, platinum, palladium, or combinations thereof. In one embodiment, a multifunctional organometallic probe comprises a core of metal atoms surrounded by a shell of organic moieties covalently attached to the metal atoms, a fluorescent molecule, e.g., fluorescein, covalently attached to one of the organic moieties, and a targeting molecule, e.g., an antibody, covalently attached to another of the organic moieties.

Therefore it would have been obvious by the time the invention was made to use multifunctional organometallic probe for the method of Yguerabide. The motivation is covalently linking fluorescent molecules to small organometallic particles circumvents the difficulties in two significant ways: first, the fluorescent molecule and the targeting molecule are covalently attached and will not desorbs. The attachment can be performed in mild physiological buffers, thus eliminating the very low ionic strength conditions necessary for colloidal gold conjugation. Thus molecules difficult to attach to colloidal gold are simply and more stably attached by this covalent route. Secondly, the metal particle chosen does not significantly quench the fluorescence, in sharp contrast to colloidal gold. In many cases, full fluorescent activity is maintained. The success of these new dual conjugates (combining fluorescence and metal, e.g., gold) permits unique applications such as fluorescent immunolabeling which is discernible by light or

confocal microscopy; when cells exhibiting optimal distribution of the probe are identified, these may be processed for electron microscopy so that high resolution ultrastructure localization of antigens may be performed. By using a dual label, there is no question as to the distributions being identical. This type of probe has long been sought by cell biologists.

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jezia Riley whose telephone number is 703-305-6855. The examiner can normally be reached on 9:30AM - 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 703-308-1119. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

11/14/03

PRIMARY EXAMINER